| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.6 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.6 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.053 | 0.6 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.6 |